Together, we can redefine cancer treatment—and create more hope than ever before.

OnCusp is actively expanding its portfolio of oncology assets. We partner with biotechnology firms, pharmaceutical companies, and academic researchers seeking to accelerate development of their first-in-class or global top 3 preclinical assets. Partnership models and deal structures are flexible, but we are always guided by our core principle that maximum value creation occurs when interests are aligned. Our capital-efficient model, rigorous clinical trials, and global licensing network can unlock the best outcome possible for partnered assets.